Brief: Biogen To Pause Or Terminate Investment In Majority Of Legacy Apellis Research Programs, Says Spokesperson
26/06/2026 12:56
BRIEF-Biogen To Pause Or Terminate Investment In Majority Of Legacy Apellis Research Programs, Says Spokesperson June 26 (Reuters) - Biogen Spokesperson:
BIOGEN SPOKESPERSON - CONDUCTING COMPREHENSIVE REVIEW OF FORMER APELLIS CLINICAL PRECLINICAL PORTFOLIO TO FURTHER EVALUATE STRATEGIC FIT
BIOGEN SPOKESPERSON: BIOGEN MADE THE DECISION TO PAUSE OR TERMINATE INVESTMENT IN THE MAJORITY OF LEGACY APELLIS RESEARCH PROGRAMS
BIOGEN SPOKESPERSON: A SMALL NUMBER OF ROLES WITHIN THE RESEARCH ORGANIZATION HAVE BEEN ELIMINATED
Further company coverage: BIIB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout